|
|
Gastroenterology 2025 - LIVE STREAMING
The Comprehensive 2025 Gastroenterology Update
This highly rated Harvard Medical School CME program ensures participants are current with state-of-the-art GI strategies and clinical practices. It covers recent advances and their impact on clinical approaches and on patient outcomes. Updates, best practices, and new guidelines are presented by nationally recognized GI experts and master clinicians.
Practical, Results-Driven Education
Highlights of the 2025 program include:
• The new... |
|
|
Establishing Frameworks for Precision Medicine in NTRK Fusion-Positive Advanced Solid Tumors
Despite significant advancements over the past decade, significant unmet needs persist for patients with NTRK-positive locally advanced or metastatic solid tumors. In addition, there is ongoing debate about the importance of testing for genomic alterations in rare cancers, or those that rarely occur in common cancers. However, evolving molecular testing procedures and emerging therapeutic options targeting NTRK fusions offer new pathways for the detection and treatment of these cancers. To he... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). Multicancer early detection (MCED) is an emerging form of blood-based testing that utilizes cancer biomarkers in the blood to screen for multiple cancers simultaneously (ACS, 2024). Currently, numerous clinical trials are investiga... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States (ACS, 2024; Pinsky & Berg, 2012; USPSTF, 2024). Multicancer early detection (MCED) is a novel form of blood-based ca... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Treating SCLC in the Relapsed/Refractory Setting: Giving Patients a Voice About Second-Line Therapy
SCLC is aggressive in nature with a high recurrence rate following initial treatment and a propensity to become resistant to conventional therapies. Early detection is critical, but many patients are diagnosed at an advanced stage where prognosis is poor. Progress in the second-line setting offers new hope for improving patient outcomes, but the rapid pace at which these advances are occurring present challenges for effectively integrating novel therapies into patient care. In fact, research s... |
|
|
Podcast: Multidisciplinary Task Force: Diagnosis and Management of Dedifferentiated Liposarcoma
STATEMENT OF NEED
Dedifferentiated liposarcoma (DDLPS) is an aggressive subtype of soft tissue sarcoma. Detection of MDM2 and/or CDK4 amplification distinguishes DDLPS from other types of undifferentiated sarcomas. Diagnosis of DDLPS remains challenging due to its complex karyotypes, quantitative genomic profiles, and pleomorphic pathological features (Nishio et al, 2021; Shen et al, 2022). Currently, surgical resection with or without radiation is the mainstay of treatment for localized di... |
|
|
Targeting the PI3K/AKT/PTEN Pathway for Treatment of Breast Cancer: Innovative Solutions for Equitable Care
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
The PI3K/AKT/PTEN pathway has emerged as a key player in breast cancer development. Notably, up to 50% of patients with hormone receptor"positive, human epidermal growth factor receptor 2"negative (HR+/HER2-) breast cancer have actionable biomarkers within this pat... |
|